Oppenheimer reconfirms Dexcom’s purchase ratings in the HHS wearable push
Dexcom, Inc. (NASDAQ:dxcm) rank between Best stocks to buy according to hedge funds. Oppenheimer responded to Dexcom, Inc. on June 24th in response to comments by Health and Human Services Secretary RFK Jr. regarding his critical wearable campaign. (NASDAQ:DXCM) price target and rating of $95 has been reconfirmed.
At a hearing of the House Energy and Commerce Health subcommittee on June 24, Secretary Kennedy declared that HHS would soon launch “one of the biggest advertising campaigns in HHS history,” promoting wearables for Americans and highlighting the benefits of glucose monitors.
As Oppenheimer pointed out, the potential for major government marketing campaigns is encouraging for companies that provide ongoing glucose monitoring (CGM).
Oppenheimer also noted recent advances in CGM coverage for non-insulin type 2 diabetes, referring to a Dexcom-led randomized controlled trial that is expected to be wrapped in late 2025 or early 2026 in patients with non-insulin type 2 diabetes.
Dexcom, Inc. (NASDAQ: DXCM) is a medical device company that manufactures continuous glucose monitoring (CGM) systems that allow real-time health management control.
Although we acknowledge the potential of DXCM as an investment, we believe certain AI stocks offer greater promotion potential and pose a risk of decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.
read more: 10 Best Magic Formula Stocks of 2025 and Best Retirement Stocks to Buy According to Hedge Funds
Disclosure: None.